Eiken Chemical

Basic Information

Stock Code
4549
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
February 1939
Listing Year
January 1990
Official Website
https://www.eiken.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Towns, Atect, Kainos, Institute of Immunology, Mizuho Medy, Asaka Kogyo, Cosmos, Sysmex, CSP

Overview

Eiken Chemical is a major pharmaceutical testing reagent company founded in 1939, with clinical testing reagents as its main business, holding approximately 60% domestic market share in fecal occult blood testing.

Current Situation

Eiken Chemical recorded consolidated sales of approximately 43 billion yen, operating profit of about 8.4 billion yen, and net profit of about 6.2 billion yen for the fiscal year ended March 2022. Its flagship fecal occult blood testing reagents and devices hold about 60% share in Japan, and are also sold in Europe, the Americas, and Asia. It has independently developed gene amplification technology called the LAMP method and provides innovative products such as rapid gene testing kits for tuberculosis. It is promoting global expansion through business alliances with Otsuka Pharmaceutical and the establishment of a subsidiary in China. It maintains stable production with two bases in Tochigi Prefecture. As part of social contributions, it publishes academic journals and supports regional medical activities, emphasizing corporate social responsibility. In the future, it aims for growth through expansion in the gene testing field and strengthened sales in international markets. Based on its latest management vision 'EIKEN WAY,' it focuses on technological innovation and sustainable business operations.

Trivia

Interesting Facts

  • Established in 1939, a long-standing pioneer in clinical test reagents since pre-war era.
  • Maintains approximately 60% domestic market share in fecal occult blood testing.
  • Proprietary LAMP method contributes to rapid infectious disease diagnosis.
  • Strengthened funding and technology base through capital alliance with Otsuka Pharmaceutical.
  • One of few Japanese companies able to provide integrated test reagents and devices.
  • Handles not only medical but also food and environmental test reagents.
  • Actively expanding in Asia with 100% subsidiary in China.
  • Regularly publishes academic journal 'Modern Media' for information dissemination.
  • LAMP method is patented technology acquired in countries worldwide.
  • Introducing AI technology into test devices to improve accuracy.
  • Corporate stance actively engaging in environmental and social contribution activities.
  • Technological prowess in successfully commercializing Japan's first powdered culture media.
  • Expands market through bundled sales of test reagents and devices.
  • Tuberculosis rapid test kit is one of WHO-recommended products.
  • One of Nikkei's major listed companies in bio and pharmaceuticals related sector.

Hidden Connections

  • Capital alliance with Otsuka Pharmaceutical also links to new drug development support.
  • LAMP method technology utilized in infectious disease countermeasures in various countries.
  • Numerous joint research projects with pharmaceutical companies and medical institutions.
  • Accelerated Asia market strategy through establishment of China subsidiary.
  • Test devices widely supplied to testing centers domestically and internationally.
  • Promotes differentiation from competitors with proprietary gene technology.
  • Expanding distribution network through alliances with medical device sales companies.
  • Strong relationships with medical community through social contribution activities.

Future Outlook

Growth Drivers

  • Expansion of gene testing market and increasing demand for infectious disease testing.
  • Growing demand for cancer screening domestically and internationally.
  • Expansion of new test product lines utilizing LAMP method.
  • Increasing needs for digitalization and automation in medical institutions.
  • Acceleration of overseas market development centered on Asia.
  • Growing importance of health management and preventive medicine in aging society.
  • Enhanced technology and sales capabilities through strengthened alliance with Otsuka Pharmaceutical.
  • Value-added expansion through AI and IoT integration in test devices.
  • Business diversification into food and environmental testing fields.
  • Expected market expansion from regulatory easing and legal system improvements.

Strategic Goals

  • Achieve over 70% domestic share in fecal occult blood testing.
  • Expand world market share in LAMP method-related products.
  • Expand overseas sales ratio to over 30%.
  • Realize sustainable production system and reduced environmental impact.
  • Promote technological innovation through continuous expansion of R&D investment.
  • Build test systems leveraging AI and digital technology.
  • Promote market launch and penetration of new infectious disease test products.
  • Expand joint business areas with Otsuka Pharmaceutical.
  • Strengthen regional medical support and social contribution frameworks.
  • Improve customer satisfaction with high-quality products and services.

Business Segments

Clinical Test Reagent Manufacturing

Overview
Business division specializing in manufacturing and providing clinical test reagents for medical institutions.
Competitiveness
Development of high-precision test reagents utilizing proprietary technologies such as LAMP method
Customers
  • Hospitals and Clinics
  • Testing Centers
  • Public Hygiene Laboratories
  • University Medical Departments
  • Test Reagent Importers and Distributors
Products
  • Fecal Occult Blood Test Reagents
  • Immunoserological Test Reagents
  • Urinalysis Test Strips
  • Microbial Test Culture Media
  • Gene Test Kits

Test Device Sales

Overview
Provides sales and maintenance of in-house test devices to medical institutions.
Competitiveness
Supply of test devices that balance ease of use and high performance
Customers
  • Hospital Equipment Managers
  • Clinics
  • Medical Device Trading Companies
  • Overseas Medical Institutions
  • Public Testing Organizations
Products
  • Fecal Occult Blood Test Devices
  • Immunoserological Analysis Devices
  • Urinalysis Devices
  • Microbial Test Devices
  • Gene Test Devices

R&D Support Services

Overview
Contract services supporting research and development in medical and biotech fields.
Competitiveness
Technical support based on long years of clinical testing expertise
Customers
  • University Labs
  • Pharmaceutical Development Companies
  • Public Research Institutions
  • Biotechnology Companies
Products
  • Research Reagent Provision
  • Technical Support
  • Joint Research Framework Establishment

Overseas Business

Overview
Exports and sells test reagents and devices mainly in Europe, Americas, and Asia.
Competitiveness
Adaptability to international markets and partnership networks
Customers
  • Overseas Medical Institutions
  • Local Distributors
  • International Health Organizations
  • Exporters
Products
  • Overseas Fecal Occult Blood Test Reagents
  • Overseas Gene Test Kits
  • Test Devices

Health Checkup Related Equipment and Supplies

Overview
Area providing equipment and consumables related to health checkups.
Competitiveness
Multi-functional and user-friendly test product lineup
Customers
  • Health Checkup Centers
  • Corporate Health Checkup Managers
  • Medical Device Sales Companies
Products
  • Blood Collection Tools
  • Centrifuges
  • Specimen Collection Sets

Food and Environmental Microbial Testing

Overview
Manufacturing and sales of reagents for food safety and environmental hygiene testing.
Competitiveness
Rapid and highly reliable testing technology
Customers
  • Food Factories
  • Hygiene Management Companies
  • Environmental Testing Organizations
Products
  • Microbial Test Reagents
  • Environmental Test Kits

Competitive Advantage

Strengths

  • High market share in fecal occult blood testing technology
  • Proprietary LAMP method gene technology
  • Diverse lineup of reagents and devices
  • Strong alliance with Otsuka Pharmaceutical
  • Supply capacity from stable production bases
  • Abundant domestic and international sales channels
  • Continuous R&D investment
  • Presence of personnel with specialized knowledge
  • Excellent product quality control system
  • Reliability from extensive experience
  • Active social contribution activities
  • Global market expansion capabilities
  • Strong patent and IP protection system
  • Ability to serve diverse customer segments
  • High test accuracy and reliability

Competitive Advantages

  • Holds approximately 60% share in domestic fecal occult blood testing market
  • Developed rapid and high-sensitivity gene testing using LAMP method technology
  • Strengthened in capital and technology through capital and business alliance with Otsuka Pharmaceutical
  • Covers wide customer needs with diversified product portfolio
  • Ensures stable supply with two domestic production bases
  • Improved recognition in international markets through sales in Europe, Americas, and Asia
  • Enhanced brand reliability through academic journal publication and social contributions
  • Improving test accuracy through linkage with high-quality test equipment
  • Enables long-term relationship building with customer-centric service system
  • Maintains competitive edge through acquisition of proprietary patented technologies
  • Continuously creates next-generation technologies through R&D investment
  • Competitive strength from diverse product range in various test areas
  • Contributes to infectious disease countermeasures with rapid gene testing
  • High evaluation from medical institutions for reliable products and services
  • Strengthened market coverage through diverse sales channels

Threats

  • Potential intensification of price competition from new entrants
  • Risk of product approval delays due to stricter regulations
  • Competitive pressure from rapid technological innovations in gene testing
  • Intensified competition with local players in overseas markets
  • Uncertainty from sudden fluctuations in market demand due to new infectious diseases etc.
  • Increased overseas transaction costs due to exchange rate fluctuations
  • Risk of reduced testing demand from changes in medical systems
  • Supply disruptions from disasters at production bases
  • Risk of IP infringement or counterfeit products entering the market
  • Impact from changes in major clients' business environment
  • Risk of export restrictions due to escalating international tensions
  • Rising labor costs from intensified talent acquisition competition

Innovations

2024: Enhanced functionality of rapid gene test kits

Overview
Achieved improved sensitivity and shortened testing time for tuberculosis rapid test products.
Impact
Accelerates infectious disease diagnosis and improves diagnostic accuracy

2023: Expansion of LAMP method applications

Overview
Began applying LAMP method to new gene test target diseases.
Impact
Expands test market and covers diverse disease diagnoses

2022: Introduction of AI analysis to fecal occult blood test devices

Overview
Equipped with automatic judgment system for test results using AI technology.
Impact
Contributes to improved judgment accuracy and work efficiency

2021: Strengthened digital integration of products

Overview
Promoted linkage between test devices and data management systems.
Impact
Achieved efficient test data management and utilization

2020: Development of new microbial culture media

Overview
Commercialized revolutionary culture media for rapid pathogen detection.
Impact
Contributes to shortened testing time and improved diagnostic accuracy

Sustainability

  • Promoting eco-design of products to reduce environmental impact
  • Energy conservation and CO2 emission reductions at headquarters and factories
  • Continuous efforts to improve waste recycling rates
  • Contributions to social health promotion through regional medical support
  • Maintenance and strengthening of transparent governance system
  • Establishment and implementation of sustainable material procurement standards